Patient dies in Bristol Myers Squibb autoimmune CAR-T trial
Bristol Myers Squibb disclosed a participant death in an early-stage study of an investigational CAR-T therapy for autoimmune disease.
TL;DR
- The company disclosed a participant death in an early-stage autoimmune CAR-T trial.
- Reuters reported the study involved an experimental therapy for multiple sclerosis.
- The reports do not establish causality or a broader risk rate.
STAT reported the disclosure on October 23. Reuters separately reported a death in a study of Bristol Myers Squibb’s investigational cell therapy. [1] [2]
The study involved zolacabtagene autoleucel, or zola-cel, in people with multiple sclerosis, according to Reuters coverage. Becker’s Hospital Review also reported the company disclosure. [2] [3]
Reports described septic pneumonia and timing after treatment, but did not establish that the therapy caused the death. This is an individual safety event in an investigational trial. [1] [2] [3]
The coverage does not provide a complete trial dataset, event rate or regulator assessment. Causality and any protocol changes remain open. [1] [2]
Why it matters
The disclosure is a concrete safety event in a field exploring CAR-T beyond cancer. It merits attention without drawing causal or class-wide conclusions from one reported death.
Editor's note
Cross-checked with STAT, Reuters and Becker’s Hospital Review. Causality is not established.